All News

Pts w/ pre-existing rheumatic conditions 3.6 times likelier to new rheumatic disease features or worsening disease after starting ICI for melanoma, Abs 0756 #ACR22 @RheumNow https://t.co/s1f1QxmJzA https://t.co/6cKllBzqJn

Rheumatic Toxicities of Immune Checkpoint Inhibitors in Patients with Advanced …

Osteoporotic fx in AS Abstract #0388 #ACR22 @RheumNow 🦴2k adults in RISE, mean age 68y, 44% female, 76% white 🦴Higher risk with: older age, increased comorbidity index, OP history, chronic use of opioids, low BMI 🦴Men and women were equally likely to fracture

Multiplex peripheral blood in 200+ ILD pts Differences in IL-17 RD-ILD>IPF> IPAF Higher IL-13 strongly asso w/ non-progression of ILD in RD-ILD, IPF & IPAF OR 0.4 Almost surprising considering known profibrotic role of IL-13 🧐 https://t.co/21UMq6w9hI Abs#1109 #ACR22 @Rheumnow https://t.co/7tfk74zH8A

High Interleukin-13 Level Is Associated with Disease Stability in Interstitial …

#ACR22 Abstr#0826 2 years on since FDA approved #Tocilizumab in Adults Onset Still's Disease, real-world data from Japan affirmed its effectiveness and as a steroid-sparring agent @RheumNow https://t.co/jbmhEnGwXO

Stop repeating the #ANA test! 46% of all ANA tests were repeat tests in this study. #HealthCareCost #NoUtility #ChooseWisely abst#1278 @rheumnow #ACR22 https://t.co/K7oyqJYvi9

ANA Testing Practices in the United States: A Population-Based Study Between 20…

Limited utility for using bone turnover markers in osteoporosis. Perhaps useful to assess adherence to oral therapy. @RheumNow #ACR22 #osteoporosis https://t.co/g6f7SnOzNR

Puechal et al RTX vs CYC induction in GPA: target trial emulation study. BVAS 0 and pred=<10mg at 6 months 73% RTX vs 40% CYC. RR 1.82[95%CI:1.22;2.73] @RheumNow #ACR22 Abstr#1084 https://t.co/6e8wutMC2H https://t.co/OpeajFVdJf

Rituximab versus Cyclophosphamide for Induction Therapy in Granulomatosis with …

#ACR22 Advancing Telemedicine in Rheumatology '60% prefer telemedicine for routine visits and review lab results' https://t.co/HUgoocXodE @RheumNow #ACR22

https://onlinelibrary.wiley.com/doi/epdf/10.1002/acr.24860

Tofa 5 mg BID successful in treating refractory uveitis in reducing inflammation and reducing steroid dosage. Abs 1041 #ACR22 @RheumNow https://t.co/dtAEhW7dEG https://t.co/Xbw2iEsYHh

Tofacitinib in Refractory Uveitis – an Observational Study - ACR Meeting Abstra…

#abs0948 #acr22 @rheumnow perception on fertility&ART in pts w/rheum Dx: 60% believe their Dx affects fertility/25% believe meds do: most cited MTX, steroids, TNFi, HCQ, NSAIDs. 92% heard of ART but unsure if safe or successful w/their Dx. Hx of infertility 29%/only 52% go w/ART https://t.co/lmaM773gP5

There are good reasons why you might want to treat pre-RA. Hard to walk past this promise #ACR22 @RheumNow https://t.co/YHmIl5dsID

Did you know? Teratogens may take the form of: ✳️Drugs & chemicals ✳️Physical agents ✳️Infections ✳️Metabolic conditions #ACR22 @Rheumnow #MedTwitter https://t.co/GfHL28RYjm

USA vs Canada It's kicking off and a super hot topic The Great Debate: To Treat or Not? The Role of DMARDS in Subclinical Rheumatoid Arthritis Holers/Deane (treat 🇺🇸) El Gabalawy/Pope (don't treat 🇨🇦) What more do you want, #ACR22? Bring it on @RheumNow https://t.co/DroQdnSQHf

Terrier @TerrierBen et al Mepolizumab in vasculitic type EGPA in MIRRA. Vasculitic features similar in patients who did/did not achieve remission. Decreased flares of all type, including vasculitic. @RheumNow #ACR22 Abstr#1075 https://t.co/0MkJvnCnf1 https://t.co/ZxbDqlvgae

Efficacy of Mepolizumab in Patients with Eosinophilic Granulomatosis with Polya…

Favorable kidney outcomes observed for BEL vs PBO in pts with SLE, including fewer kidney flares, greater kidney improvement (SELENA-SLEDAI), less kidney worsening (BILAG), and improved eGFR. Abs 0352 #ACR22 @RheumNow https://t.co/w50uEYVDup https://t.co/JyKZEZG6DZ

The Effect of Belimumab (BEL) on Kidney Outcomes in SLE: Results of a Large Int…

Bekker et al. Safety of avacopan across 3 trials. Rates of AEs, SAEs, infection all lower in avacopan group. @RheumNow #ACR22 Abstr#1077 https://t.co/n4zhC2zf8k https://t.co/Q8raSEERah

Safety of Avacopan in ANCA-Associated Vasculitis: Combined Data from Three Clin…

#ACR22 Abstr# Interesting data for IMID patients who had #COVID. A cohort study in Norway (1/3 had RA and mostly on TNFi; 6% RTX) showed greater anti-Spike Ab in 4th vaccine vs 3rd dose. However, the greatest was in those with 3 x doses + COVID infection (Hybrid) @RheumNow https://t.co/hGFSGqJtBT

Benavides-Villanueva et al. Single centre 28 case series of IVIG in AAV. Used due to relapse in 25, concomitant infection in 3. BVAS 0 in 56.5% at month 24, glucocorticoid sparing effect. @RheumNow #ACR22 Abstr#1079 https://t.co/wfg1HSKM9O https://t.co/DuReVU2jA4

Intravenous Immunoglobulin in Antineutrophil Cytoplasmic Antibody-associated Va…

Abs 0714 at #ACR22 real-world obs study finds seropositive and seronegative RA patients had similar clinical effectiveness 1 year after starting bDMARD or JAKi. @RheumNow https://t.co/UrVgZ0zVno https://t.co/LnXMfOkQIp

Real-World Treatment Effectiveness of Disease-Modifying Anti-Rheumatic Drugs by…

Early TNFi use and cardiovascular events in AS Abstract #0415 #ACR22 @RheumNow 📍17.6k patients, 91% male, 80% white 📍TNFi initiators were younger with lower prev. of HTN and DM 📍TNFi was associated with higher risk of incident CVD, CVA, and MACE https://t.co/7bCkfk7EYY

Topics

All News

Do you get our email newsletter?